本帖最后由 老马 于 2012-1-13 21:20 编辑 . o8 @' M) z; g0 J: i: n
9 \% ]! E9 f) l3 B4 Z爱必妥和阿瓦斯丁的比较* n5 q* n7 w- `3 |
2 e K z& N/ \0 p. R8 g3 ^2 |
http://cancergrace.org/lung/2008/08/30/bms099-os-neg/
B0 G" x% g# j7 ~! D) @! L: N \
6 Z% i& i& g3 p
- c% j; }& R- n1 p# x# ~2 m% E
http://cancergrace.org/lung/2007/12/27/platgem-erbitux-trial/
' M, U3 l9 [5 J( Z) y==================================================
+ [/ q2 R: Q. [! t# e- }Overall survival with cisplatin–gemcitabine and bevacizumab or placebo as first-line therapy for nonsquamous non-small-cell lung cancer: results from a randomised phase III trial (AVAiL)4 }. M* b- C9 n/ ~
Patients and methods: Patients (n = 1043) received cisplatin 80 mg/m2 and gemcitabine 1250 mg/m2 for up to six cycles plus bevacizumab 7.5 mg/kg (n = 345), bevacizumab 15 mg/kg (n = 351) or placebo (n = 347) every 3 weeks until progression. Primary end point was progression-free survival (PFS); OS was a secondary end point.2 F3 k' t- C) d+ I0 N0 ~. Z* |, Y
Results: Significant PFS prolongation with bevacizumab compared with placebo was maintained with longer follow-up {hazard ratio (HR) [95% confidence interval (CI)] 0.75 (0.64–0.87), P = 0.0003 and 0.85 (0.73–1.00), P = 0.0456} for the 7.5 and 15 mg/kg groups, respectively. Median OS was >13 months in all treatment groups; nevertheless, OS was not significantly increased with bevacizumab [HR (95% CI) 0.93 (0.78–1.11), P = 0.420 and 1.03 (0.86–1.23), P = 0.761] for the 7.5 and 15 mg/kg groups, respectively, versus placebo. Most patients (~62%) received multiple lines of poststudy treatment. Updated safety results are consistent with those previously reported.
& U. i$ Q" j* j9 _" b0 Y! w7 L( C
|